SCHEMBL16212460

SCHEMBL16212460

COc1nc(C)cc(Cl)c1C#N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.53
POLB P06746 2/20 0.49
TSHR P16473 2/20 0.49
MAPK1 P28482 1/20 0.49
GSK3A P49840 1/20 0.47
GSK3B P49841 1/20 0.47
DYRK1A Q13627 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
SQOR Q9Y6N5 3/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.41
CYP3A4 P08684 1/20 0.41
KDM4E B2RXH2 7/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 4/20 0.41
GAA P10253 2/20 0.41
HSD17B10 Q99714 2/20 0.39
MAPK8 P45983 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2673753 0.81 RECQL (0.71) RECQLPOLBTSHRMAPK1CYP1A2
SCHEMBL18556082 0.81 POLB (0.48) POLBSQORKDM4EALDH1A1HPGD
SCHEMBL4071607 0.80 RECQL (0.59) RECQLPOLBTSHRMAPK1CYP1A2
SCHEMBL15173851 0.80 RECQL (0.54) RECQLPOLBTSHRMAPK1SQOR
SCHEMBL20920951 0.79 MAPK8 (0.56) RECQLPOLBTSHRMAPK1GSK3A
SCHEMBL15174110 0.79 RECQL (0.53) RECQLPOLBTSHRMAPK1SQOR
SCHEMBL17343457 0.78 KDM4E (0.47) RECQLPOLBTSHRMAPK1CYP1A2
SCHEMBL9820164 0.77 KDM4E (0.46) RECQLPOLBTSHRMAPK1CYP1A2
SCHEMBL30630982 0.77 KDM4E (0.46) RECQLPOLBTSHRMAPK1CYP1A2
SCHEMBL9454917 0.77 KDM4E (0.46) RECQLTSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612390-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
CN-119954787-A Modulators of methyl-modified enzymes, compositions and uses thereof 星座制药公司 2025-05-09 CN disclosed
CN-111989325-B Modulators of methyl-modified enzymes, compositions and uses thereof 星座制药公司 2025-02-25 CN disclosed
EP-4421072-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2024-08-28 EP disclosed
US-20240116905-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2024-04-11 US disclosed
EP-3781561-B1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2024-03-13 EP disclosed
US-11274095-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2022-03-15 US disclosed
EP-3781561-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2021-02-24 EP disclosed
CN-111989325-A Modulators of methyl-modified enzymes, compositions and uses thereof 星座制药公司 2020-11-24 CN disclosed
US-20200317651-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2020-10-08 US disclosed
US-20160122342-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-05-05 US disclosed
US-20160102083-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-04-14 US disclosed
US-20160102083-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-04-14 US disclosed
EP-3004096-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2016-04-13 EP disclosed
EP-2991980-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2016-03-09 EP disclosed
WO-2015023915-A1 INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-02-19 WO disclosed
WO-2014195919-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2014-12-11 WO disclosed
WO-2014195919-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2014-12-11 WO disclosed
WO-2014177982-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2014-11-06 WO disclosed
WO-2014177982-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116905-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TPMT, TET1, DNMT1 RECQL 1720/4885POLB 508/4885TSHR 4271/4885
US-20200317651-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TPMT, TET1, DNMT1 RECQL 1720/4885POLB 508/4885TSHR 4271/4885
US-20160122342-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, BMI1, EZH1 RECQL 3615/4885POLB 1958/4885TSHR 3333/4885
US-20160102083-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, BMI1, EZH1 RECQL 3615/4885POLB 1958/4885TSHR 3333/4885
US-11274095-B2 Modulators of methyl modifying enzymes, compositions and uses thereof TPMT, TET1, DNMT1 RECQL 1720/4885POLB 508/4885TSHR 4271/4885
US-12612390-B2 Modulators of methyl modifying enzymes, compositions and uses thereof NSD1, DOT1L, EHMT2 RECQL 1669/4885POLB 157/4885TSHR 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.